Protalix BioTherapeutics (PLX) Accounts Payables (2010 - 2026)

Protalix BioTherapeutics' Accounts Payables history runs 17 years deep, the most recent figure standing at $4.3 million for Q1 2026.

• On a quarterly basis, Accounts Payables rose 3.98% year-over-year to $4.3 million in Q1 2026; TTM through Mar 2026 was $4.3 million, a 3.98% increase from a year earlier, with the FY2025 full-year figure at $5.3 million, up 16.02% from the prior year.
• Accounts Payables retreated to $4.3 million in Q1 2026 per PLX's latest filing, from $5.3 million in the prior quarter.
• Across five years, Accounts Payables topped out at $19.6 million in Q3 2024 and bottomed at $3.1 million in Q3 2023.
• The 5-year median for Accounts Payables is $5.9 million (2022), against an average of $8.9 million.
• Biggest YoY gain for Accounts Payables was 528.68% in 2024; the steepest drop was 76.65% in 2024.
• Year by year, Accounts Payables stood at $5.9 million in 2022, then slipped by 26.31% to $4.3 million in 2023, then advanced by 4.93% to $4.5 million in 2024, then grew by 16.02% to $5.3 million in 2025, then decreased by 18.52% to $4.3 million in 2026.
• Per Business Quant, the three latest PLX Accounts Payables figures stand at $4.3 million (Q1 2026), $5.3 million (Q4 2025), and $5.4 million (Q3 2025).